Helicobacter Pylori

Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic bacterium that leads to chronic inflammation of the inner lining of the stomach (gastritis), causing impairment of gastric physiology. H. pylori infection has been associated with the development of peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Currently, various antibiotics (e.g., amoxicillin, clarithromycin) and proton pump inhibitors (e.g., dexlansoprazole, omeprazole) have been used in the treatment of H. pylori infection. Due to the emergence of antibiotic-resistant bacteria, however, it is necessary to seek more effective treatments for H. pylori infections.

Creative Biolabs is an outstanding expert in the field of antibacterial drug discovery. Equipped with a first-in-class technical platform and rich expertise in antibacterial drug discovery, we offer the best one-stop solutions for antibacterial drug discovery to promote your project success.

Introduction of H.Pylori

H. pylori is a member of the genus Helicobacter that is responsible for gastrointestinal morbidities such as gastritis, peptic ulcer disease, primary gastric B-cell lymphoma and (indirectly) gastric adenocarcinoma worldwide. H. pylori are transmitted through exposure to contaminated food or water or pass from person to person through direct contact with saliva, vomit or fecal matter. Many people with H. pylori infections have few or no symptoms, while chronic infection may experience some symptoms from mild to severe gastritis. Early exposure to H pylori is related to gastric damages, progressing from atrophic gastritis to gastric ulcers and carcinoma. Individuals with H. pylori infection have a high risk of gastric diseases. In people infected with H. pylori, the lifetime prevalence of peptic ulcer is 10 to 20 percent, and the incidence of gastric cancer is 1 to 2 percent.

Fig.1 The dynamic of transmission of H. pylori infection in family members and H. pylori status of the index parent. (Malaty, 2007)

Treatment of H.Pylori Infection

Eradication of H. pylori can greatly reduce the incidence of stomach diseases. It has been revealed that eliminating H. pylori from patients with gastric mucosa-associated lymphoid tissue lymphoma resulted in a 60% to 80% regression of the lymphoma. A variety of antibiotics have been used to eradicate H. pylori from the stomach, such as amoxicillin and clarithromycin. However, H. pylori are difficult to eradicate from the stomach with antibiotics because of antibiotic resistance. H. pylori eradication rates are decreasing over the past several years due to the worldwide increase of clarithromycin resistance. To prevent the emergence of resistance, in general, two or more antibiotics are usually given together with a proton pump inhibitor medication against H. pylori infection.

Services

With years of experience in the field of antibacterial drug discovery, Creative Biolabs is confident in offering the first-class service of anti-H. pylori drug discovery for all global customers. Our service packages include target identification and validation, Hit identification, Hit to lead, Lead optimization, and IND enabling. We also can customize optimal solutions according to your special purpose.

Features

• One-stop anti-H. pylori drug discovery solution from scheme design, implementation to interpretation
• Advanced and powerful drug development platform
• Excellent scientist team providing end to end technique guidance
• Rapid order processing and fast turn-around times

If you are interested in our services, please don’t hesitate to contact us for more information and a detailed quote.

Reference

1. Malaty, H.M. Epidemiology of Helicobacter pylori infection. Best Practice & Research Clinical Gastroenterology. 2007, 21(2): 205-214.

For Research Use Only.